Article Text

Download PDFPDF

At a glance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

VEGF trap-eye for diabetic macular oedema

VEGF Trap is a human recombinant fusion protein consisting of the binding domains of VEGF receptors and Fc domain of IgG. Compared with ranibizumab, VEGF Trap has a longer half-life after intraocular injection, a higher binding affinity to VEGF-A, and binds other members of the VEGF family. Do et al assessed the safety and bioactivity of a single intravitreal injection of VEGF Trap-Eye (4.0 mg) in five subjects with diabetic macular oedema. No ocular toxicity was observed. At 6 weeks, four of the five patients showed improvement in foveal thickness (31% reduction from baseline) and improvement in BCVA (three letters).

See pages 144

Intravitreal bevacizumab for myopic choroidal neovascularisation

Choroidal neovascularisation is one of the significant sight-threatening complications in pathological myopia. Chan et al performed a prospective study to examine the 1-year results of intravitreal bevacizumab in 29 patients with myopic CNV. The patients received 3 initial monthly injections; additional monthly injections were performed in …

View Full Text

Linked Articles